Features Screener Stocks Charts
Sign In Sign Up

Alembic Pharma Cash Flow Statement

NSE:APLLTD | PHARMACEUTICALS

Showing 2 of 10 years of data. Sign up free for 3 years, or upgrade for full access.

View Plans

Cash Flow Insights

Cash Conversion

0.12x

APLLTD's operating cash flow was significantly below net income in FY 2025, suggesting earnings include substantial non-cash items.

Free Cash Flow

₹-4.76B

APLLTD's free cash flow was negative at ₹-4.76B in FY 2025, down 200.0% from FY 2024. The company spent more on capital investments than it generated from operations.

Dividend Coverage

-2.2x

APLLTD's free cash flow did not fully cover dividends in FY 2025. The company may be funding dividends from reserves or borrowings.

CapEx Intensity

640.7%

Capital expenditure consumed 640.7% of operating cash flow in FY 2025 for APLLTD, typical of capital-intensive industries.

2-year APLLTD cash flow snapshot

Hover the chart icon for YoY change.

FY 2024 - FY 2025
Item Chart 2024 2025
Net Income 6.32B 7.07B
Cash flow Operating Activities 8.03B 879.70M
Investments in PPE -3.27B -5.64B
Cash flow Investing Activities -3.21B -5.68B
Dividend Paid -1.57B -2.16B
Cash flow Financing Activities -4.38B 4.44B
Cash at beginning of period 754.80M 1.20B
Cash at end of period 1.20B 834.80M
Free Cash Flow 4.76B -4.76B

Values are shown in millions (M) and billions (B). All amounts are in Indian Rupees (₹).

Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: Mar-2025